Rigel Pharmaceuticals Inc
RIGL· Nasdaq
RIGLRigel Pharmaceuticals Inc
Released Aug 6, 2024, after the close
10-Q filed Aug 6, 2024, 37 days after period end · 0001558370-24-011079
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $36.84M | $26.89M | $29.82M | $26.27M |
| Net Income | -$1.03M | -$6.60M | -$13.49M | -$13.82M |
| EPS Diluted |
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR
| -$0.06 |
| -$0.38 |
| -$0.08 |
| -$0.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
